S
Solarea Bio
A clinical-stage biotechnology company developing plant-based microbial solutions to some of the world’s largest health problems
About Solarea Bio
Solarea Bio, based in Cambridge, MA, is a biotechnology company focused on developing innovative solutions for health disorders by utilizing bacteria and fungi found in healthy foods. The company targets inflammatory conditions, including those affecting the gut-musculoskeletal axis. Solarea Bio's primary clients include healthcare providers and patients suffering from chronic inflammatory diseases. Operating in the biotech and healthcare market, the company employs a business model centered on research and development, followed by commercialization of its microbial-based therapies. Revenue is generated through product sales, licensing agreements, and partnerships with other biotech firms. Solarea Bio recently secured $15 million in a Series B financing round led by S2G Ventures, with participation from Bold Capital Partners, Viking Global Investors, and GG 1978 SICAF SIF. This funding will support further research and development, as well as the scaling of their innovative solutions.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Waltham, United States
- Employees
- 19
- Open positions
- None listed
- Dealroom signal
- 71.9/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | May 2023 | $15M | $60M | Viking Global Investors · S2G Investments · Bold Capital Partners · GG 1978 | ↗ |
| SERIES A✓Equity / VC | Oct 2020 | $11M | $45M | S2G Investments · Bold Capital Partners · Viking Global Investors · GISEV Family Office | — |
Growth signals
Latest recorded traffic for Solarea Bio is 220 monthly website visits, down 71.4% over the last three months. Solarea Bio's team grew 72.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Social Starts
Rising Tide Fund
Series A5 investors entered at this stage
S2G Investments
Bold Capital Partners
Viking Global Investors
GISEV Family Office
GG 1978
Other known investors1 additional known investor
Joyance Partners
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Solarea Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Solarea Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.